ClinicalTrials.gg
RecruitingNCT07147348Updated Jun 15, 2026

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

A Phase 1/2 interventional study of BNT3212 and Pumitamig in Advanced Solid Tumor, sponsored by BioNTech SE. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
375
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

Read the detailed description

This study will include four parts:

  • Part A (BNT3212 monotherapy - dose escalation)
  • Part B (BNT3212 monotherapy - dose expansion cohorts)
  • Part C (BNT3212 + pumitamig combination therapy - dose escalation)
  • Part D (BNT3212 + pumitamig combination therapy - dose expansion cohorts)

This study will follow a stepwise approach, beginning with a typical dose escalation in advanced solid tumors, followed by dose expansion in a range of indications. This design allows to gradually assess safety, preliminary efficacy, potential recommended Phase 2 dose (RP2D), and indications, while ensuring an acceptable benefit-risk balance along the way. Throughout this process, clinical data, including PK, biomarker, immunogenicity, safety, and efficacy, as well as non-clinical data, will be continuously collected and evaluated to support decision-making and ensure participant safety.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • BNT3212 (or PM1300)
  • BNT327
  • Programmed death-ligand 1 (PD-L1)
  • Vascular endothelial growth factor A (VEGF-A)
  • Bispecific antibody
  • Antibody-drug conjugate (ADC)
  • Combination with other investigational agents
  • Immunotherapy
  • Antibody
  • Programmed death 1 (PD-1)
03

In context

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with or cytologically confirmed locally advanced, recurrent, or solid tumors that have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease; or for whom the standard therapy is considered inappropriate or intolerable.
  • Have at least one based on v1.1.
  • performance status of 0 (fully active, able to carry out all pre-disease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).
  • Predicted of ≥3 months.
  • ≥50% by either echocardiography or multigated acquisition scan within 28 days prior to first dose of study treatment.
  • Adequate liver, renal, hematological, and coagulation function.
  • Recovery to Grade 0-1 (or baseline) from adverse reactions related to prior anti cancer therapy except for:

    • Asymptomatic laboratory abnormalities such as elevated alkaline phosphatase, hyperuricemia, elevated serum amylase/lipase, and elevated blood glucose.
    • Toxicity that the investigator determined to have no safety risk, such as alopecia, Grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.
  • The investigator considers discontinuation of protocol-defined anti-cancer therapies and restricted medications with protocol-defined as medically acceptable.
  • For Parts B and D only: Participants must be diagnosed with specific indications.

Key Exclusion Criteria:

  • Active infection (e.g., bacterial or fungal infections) requiring systemic treatment (e.g., severe pneumonia, bacteremia, sepsis), except oral antibiotics.
  • Participants with primary central nervous system (CNS) .
  • Active , defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  • Unstable pleural effusion or ascites requiring thoracentesis or paracentesis within 14 days prior to initiation of study treatment.
  • Have active, or a history of, pneumonitis requiring treatment with steroids, or has active, or a history of, interstitial lung disease.
  • pulmonary complications.
  • History of severe cardiovascular disease.
  • Have a history of significant hematologic toxicity to , as assessed by investigator, e.g., Grade 4 febrile neutropenia or recurrent/persistent Grade 3 to 4 neutropenia.
  • Have active or chronic corneal disorders or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
  • Have uncontrolled hypertension while on antihypertensive medicine or poorly controlled diabetes.
  • Concurrent malignancy within 5 years prior to study enrollment. Exceptions: basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ after radical resection.
  • Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism).
  • Have adverse reactions from prior anti-tumor therapy that have not returned to Grade 1 (graded by v5.0 criteria) or below (unless the investigator determines that certain AEs pose no safety risk to participants, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy) are not eligible for the study.
  • For Parts C and D only: Prior treatment with /L1 and VEGF-A antibody combinations (including bispecific antibodies to PD-1/L1 and VEGF-A).
  • For Parts C and D only: Have active, or history of, disease with risk of exacerbation following PD-L1 inhibition OR an immune deficiency (e.g., hematopoietic stem cell transplantation or organ transplantation). Participants with protocol-specified conditions may be eligible.
  • For Parts C and D only: Have serious non-healing wounds, ulcer, or bone fracture.
  • For Parts C and D only: Have evidence of major coagulation disorders or other significant risks of hemorrhage.
  • For Parts C and D only: Have a history of serious Grade 3 or higher immune-related adverse events that led to treatment discontinuation of a prior immunotherapy.
  • For Parts C and D only: Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP.
  • For Parts C and D only: Have received:

    • Anticoagulant therapy for therapeutic purposes (except low molecular weight heparin) within 14 days prior to the first dose of IMP.
    • Antiplatelet drugs within 10 days prior to the initiation of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Part A - BNT3212 monotherapy (dose escalation)

    Escalating dose levels of BNT3212 to define the maximum tolerated dose (MTD) in participants with histologically or cytologically confirmed locally advanced/unresectable, recurrent, or metastatic malignant solid tumors who are refractory to or unable to tolerate standard treatment, or for whom no standard treatment is available.

    Biological: BNT3212

  • Experimental
    Part B - BNT3212 monotherapy dose level (DL)1 (expansion cohort)

    Indication-specific cohort populations will be tested.

    Biological: BNT3212

  • Experimental
    Part B - BNT3212 monotherapy DL2 (expansion cohort)

    Indication-specific cohort populations will be tested.

    Biological: BNT3212

  • Experimental
    Part B - BNT3212 monotherapy DL3 (expansion cohort)

    Indication-specific cohort populations will be tested.

    Biological: BNT3212

  • Experimental
    Part C - BNT3212 + pumitamig combination therapy (dose escalation)

    Escalating dose levels of BNT3212 plus a fixed dose of pumitamig to define the MTD in participants with histologically or cytologically confirmed locally advanced/unresectable, recurrent, or metastatic malignant solid tumors who are refractory to or unable to tolerate standard treatment, or for whom no standard treatment is available.

    Biological: BNT3212 · Biological: Pumitamig

  • Experimental
    Part D - BNT3212 DL1 + pumitamig combination therapy (expansion cohort)

    Indication-specific cohort populations will be tested. Pumitamig will be administered as fixed dose.

    Biological: BNT3212 · Biological: Pumitamig

  • Experimental
    Part D - BNT3212 DL2 + pumitamig combination therapy (expansion cohort)

    Indication-specific cohort populations will be tested. Pumitamig will be administered as fixed dose.

    Biological: BNT3212 · Biological: Pumitamig

  • Experimental
    Part D - BNT3212 DL3 + pumitamig combination therapy (expansion cohort)

    Indication-specific cohort populations will be tested. Pumitamig will be administered as fixed dose.

    Biological: BNT3212 · Biological: Pumitamig

Interventions

  • BiologicalBNT3212

    Intravenous infusion

  • BiologicalPumitamig

    Intravenous infusion

    Also known as: PM8002, BNT327

06

What researchers measure

Primary outcomes

  1. Parts A and C - Occurrence of dose limiting toxicities (DLTs) within a participant during the DLT observation period

    Per cohort.

    Time frame: Up to 28 days after first dose of investigational medicinal product (IMP).

  2. All parts - Percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs by relationship

    Per cohort. Adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for AEs version 5.0 (NCI CTCAE v5.0).

    Time frame: From the time of the first dose of IMP until 90 days after the last dose of IMP, approximately up to 31 months.

  3. Parts A and C - Percentage of participants with dose interruptions or discontinuations of study treatment due to TEAEs

    Per cohort.

    Time frame: From the time of the first until last dose of IMP, approximately up to 31 months.

  4. Parts B and D - Percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEs

    Per cohort.

    Time frame: From the time of the first until last dose of IMP, approximately up to 31 months.

  5. Parts B and D (expansion cohorts) - Objective response rate (ORR)

    Per cohort. ORR defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

Secondary outcomes

  1. All parts - PK assessment: Maximum concentration (Cmax) derived from serum/plasma concentrations

    Per cohort. For BNT3212 (conjugated antibody, total antibody, and unconjugated derivative of camptothecin, topoisomerase I inhibitor \[iCPT\]) and for pumitamig if in the combination cohorts, as data permits.

    Time frame: From predose to 28 days after first dose of IMP.

  2. All parts - PK assessment: Area under the concentration-time curve (AUC0-t) derived from serum/plasma concentrations

    Per cohort. For BNT3212 (conjugated antibody, total antibody, and unconjugated iCPT) and for pumitamig if in the combination cohorts, as data permits.

    Time frame: From predose to 28 days after first dose of IMP.

  3. All parts - PK assessment: Minimum concentration (Ctrough) derived from serum/plasma concentrations

    Per cohort. For BNT3212 (conjugated antibody, total antibody, and unconjugated iCPT) and for pumitamig if in the combination cohorts, as data permits.

    Time frame: From predose until 90 days after the last dose of IMP.

  4. All parts - Anti-drug antibody (ADA) prevalence

    Per cohort and by dose level, derived from serum samples. Prevalence defined as the percentage of participants who are ADA positive (either baseline or post baseline), if data permits.

    Time frame: For up to 90 days from the last dose of IMP.

  5. All parts - ADA incidence

    Per cohort and by dose level, derived from serum samples. Incidence defined as the percentage of participants having treatment-emergent ADA, if data permits.

    Time frame: For up to 90 days from the last dose of IMP.

  6. All parts - Disease control rate (DCR)

    Per cohort. DCR defined as the percentage of participants with confirmed CR, PR, or stable disease (per RECIST v1.1 based on the investigator's assessment) as best overall response.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

  7. All parts - Duration of response (DOR)

    Per cohort. DOR defined as the time from first confirmed objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease \[PD\] per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

  8. All parts - Progression free survival (PFS)

    Per cohort. PFS based on the investigator's assessment defined as the time from first dose of trial treatment to the first objective tumor progression (PD per RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

  9. All parts - Time to response (TTR)

    Per cohort. TTR, defined as the time from first dose of trial treatment to first confirmed objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) in participants with a confirmed objective response.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

  10. All parts - Overall survival (OS)

    Per cohort. OS defined as the time from first dose of trial treatment to death from any cause.

    Time frame: From first dose of IMP until end of study, approximately up to 31 months.

07

Study locations

14 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 29, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Aug 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07147348
Lead sponsor
BioNTech SE
Collaborators
Biotheus (Hengqin) Co., Ltd., BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Aug 27, 2025
Primary completion
Nov 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

: BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion